Bioequivalence and Bioavailability Forum

Dear All,

I'm working on a study aiming at evaluating the absolute bioavailability (BA) of an inhaled drug. I suppose that the approach to assess absolute BA is the same as for evaluating comparative BA (i.e., bioequivalence): the AUCs are compared based on an ANOVA model (please note: the same dose is inhaled and administered i.v.).

However, in several papers I found absolute BA calculated for each subject (usually reported as F) and summarized using descriptive statistics. In my opinion this second approach may be useful to provide some support to the result obtained using the ANOVA, but it can not be considered as the analysis of primary interest.

I would like to know your opinion about this point. Thank you very much for your help.